ECSP055970A - Uso de palonosetron para el tratamiento de nausea y vomito post operatorio - Google Patents
Uso de palonosetron para el tratamiento de nausea y vomito post operatorioInfo
- Publication number
- ECSP055970A ECSP055970A EC2005005970A ECSP055970A ECSP055970A EC SP055970 A ECSP055970 A EC SP055970A EC 2005005970 A EC2005005970 A EC 2005005970A EC SP055970 A ECSP055970 A EC SP055970A EC SP055970 A ECSP055970 A EC SP055970A
- Authority
- EC
- Ecuador
- Prior art keywords
- palonosetron
- nvpo
- treatment
- another aspect
- pharmaceutically acceptable
- Prior art date
Links
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 title abstract 11
- 229960002131 palonosetron Drugs 0.000 title abstract 11
- 206010047700 Vomiting Diseases 0.000 title abstract 5
- 206010028813 Nausea Diseases 0.000 title 1
- 230000008693 nausea Effects 0.000 title 1
- 230000008673 vomiting Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 8
- 150000003839 salts Chemical class 0.000 abstract 4
- 230000002265 prevention Effects 0.000 abstract 3
- 230000037396 body weight Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000003111 delayed effect Effects 0.000 abstract 2
- 230000003444 anaesthetic effect Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 229940127558 rescue medication Drugs 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Abstract
Se ha descubierto con sorpresa que una dosis bastante pequeña de palonosetrón es eficaz contra la NVPO, y que esta pequeña dosis es efectiva para prácticamente todo el tiempo que un paciente se someta a una operación quirúrgica normalmente corre el riesgo de desarrollar NVPO (normalmente dentro de las 0-36 horas de la operación). Por lo tanto, el invento ofrece en un aspecto un método completo para tratar o prevenir NVPO en una persona humana, que comprende administrar desde aproximadamente 0,025 hasta aproximadamente 0,25mg de palonosetrón o una sal farmacéuticamente aceptable del mismo en el momento de la operación. El método es efectivo contra la NVPO causada por diversas operaciones quirúrgicas y compuestos anestésicos, como se debate con más detalle a continuación.Otro aspecto se deriva de la larga duración inesperada de la acción del palonosetrón, y la facilidad del compuesto para prevenir el "establecimiento demorado" de NVPO (es decir que NVPO se presente unas 4, 6, 8, 12 ó 18 horas después de la cirugía). Por esto, en otro aspecto el invento ofrece un método de tratamiento o prevención del establecimiento demorado de NVPO que comprende la administración de una cantidad efectiva de tratamiento de palonosetrón o una sal farmacéuticamente aceptable del mismo en el momento de la operación.Otro aspecto se deriva del rápido establecimiento inesperado del palonosetrón después de la administración, y su uso como medicamento de rescate cuando se sufre NVPO inesperadamente. Por lo tanto, también en otro aspecto el invento ofrece un método de rescatar a un paciente de NVPO que comprende la administración de una cantidad efectiva de tratamiento de palonosetrón o una sal farmacéuticamente aceptable del mismo poco después del inicio de dicha NVPO. El método se realizará normalmente en más de unas 1, 2, 3, 4, 5 o 6 horas después de la operación pero dentro de las 36 horas después de la operación.La sorprendente potencia y la mayor vida media del plasma de palonosetrón también cubren diversas necesidades clínicas no cubiertas, incluidas: mayor eficacia, menor coste, menos efectos secundarios y mayor duración de la acción. Por esta razón, en otro aspecto el invento ofrece un método para el tratamiento o prevención de emesis (cualquiera que sea la causa) que comprende la administración de una sola dosis de tratamiento efectivo de palonosetrón o una sal farmacéuticamente aceptable del mismo durante un período de siete días, comenzando principalmente en el momento de presentarse la emesis. La emesis puede ser inducida por diversos procedimientos médicos, incluida quimioterapia, radioterapia y operaciones quirúrgicas.Sorprendentemente también se ha encontrado que el palonosetrón presenta una meseta de eficacia, que al combinarse con su perfil de seguridad permite administrar de forma efectiva una dosis única en una gama de pesos corporales. Por esto, en otro aspecto, el invento ofrece un método para el tratamiento o prevención de emesis (cualquiera que sea la causa) que comprende administrar una dosis definida de palonosetrón o una dosis farmacéuticamente aceptable del mismo a diferentes pacientes con diferentes pesos corporales entre unos 50 y 80 kilos de peso, cuando esta dosis definida sea la misma entre esta gama de pacientes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44834203P | 2003-02-18 | 2003-02-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP055970A true ECSP055970A (es) | 2006-01-16 |
Family
ID=32908576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005005970A ECSP055970A (es) | 2003-02-18 | 2005-08-18 | Uso de palonosetron para el tratamiento de nausea y vomito post operatorio |
Country Status (32)
Country | Link |
---|---|
US (1) | US20060074101A1 (es) |
EP (2) | EP2258367A3 (es) |
JP (1) | JP2006517944A (es) |
KR (1) | KR101113087B1 (es) |
CN (1) | CN1750822A (es) |
AT (1) | ATE490774T1 (es) |
AU (1) | AU2004212704B2 (es) |
BR (1) | BRPI0407549A (es) |
CA (1) | CA2515946C (es) |
CU (1) | CU23587B7 (es) |
CY (1) | CY1111312T1 (es) |
DE (1) | DE602004030424D1 (es) |
DK (1) | DK1596862T3 (es) |
EA (1) | EA013836B1 (es) |
EC (1) | ECSP055970A (es) |
ES (1) | ES2357769T3 (es) |
GE (1) | GEP20104908B (es) |
HK (1) | HK1076402A1 (es) |
HR (1) | HRP20050709A2 (es) |
IS (1) | IS7983A (es) |
MX (1) | MXPA05008757A (es) |
MY (1) | MY143789A (es) |
NO (1) | NO20054296L (es) |
NZ (1) | NZ541862A (es) |
PL (1) | PL378122A1 (es) |
PT (1) | PT1596862E (es) |
SI (1) | SI1596862T1 (es) |
TW (1) | TWI355936B (es) |
UA (1) | UA96254C2 (es) |
UY (1) | UY28193A1 (es) |
WO (1) | WO2004073714A1 (es) |
ZA (1) | ZA200506580B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE355275T1 (de) | 2000-10-20 | 2006-03-15 | Eisai R&D Man Co Ltd | Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen |
JP5690461B2 (ja) * | 2002-11-15 | 2015-03-25 | ヘルシン ヘルスケア ソシエテ アノニム | 化学療法誘導嘔吐を治療するためのパロノセトロン |
JO2735B1 (en) * | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
US8598219B2 (en) | 2003-01-30 | 2013-12-03 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
JP5787301B2 (ja) * | 2006-01-27 | 2015-09-30 | アデア ファーマシューティカルズ,インコーポレイテッド | 弱塩基性薬および有機酸を含む薬物送達系 |
EP2363117B1 (en) * | 2006-01-27 | 2015-08-19 | Aptalis Pharmatech, Inc. | Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids |
CA2666512C (en) * | 2006-10-24 | 2014-05-27 | Helsinn Healthcare S.A. | Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability |
TWI429436B (zh) * | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
US20090155363A1 (en) * | 2007-12-14 | 2009-06-18 | Todd Maibach | Methods for oral administration of active drugs |
JP5547065B2 (ja) | 2008-05-15 | 2014-07-09 | 久光製薬株式会社 | パロノセトロンを含有する経皮吸収製剤 |
US20100143461A1 (en) * | 2008-12-08 | 2010-06-10 | Ben-Zion Solomon | Palonosetron formulation |
ES2432618T3 (es) * | 2009-05-20 | 2013-12-04 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular |
SI2432467T1 (en) | 2009-05-20 | 2018-06-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | ANTAGONIST RECEPTOR SEROTONINA 5-HT3 FOR THE USE IN THE TREATMENT OF LEASE VESTIBULAR DISEASES |
US20110003005A1 (en) * | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
WO2011058427A1 (en) | 2009-11-13 | 2011-05-19 | Helsinn Healthcare S.A. | Palonosetron metabolites |
ES2595077T3 (es) * | 2009-11-18 | 2016-12-27 | Helsinn Healthcare Sa | Composiciones para tratar náuseas y vómitos mediados centralmente |
EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
KR101368587B1 (ko) * | 2010-12-27 | 2014-03-05 | 주식회사 삼양바이오팜 | 오심 또는 구토 방지용 조성물 |
US10071088B2 (en) | 2012-06-26 | 2018-09-11 | Precondit, Llc | Anti-nausea drug combinations |
JP2017504615A (ja) | 2013-12-23 | 2017-02-09 | サムヤン バイオファーマシューティカルズ コーポレイション | パロノセトロンを含有する薬学組成物 |
US11612605B2 (en) | 2016-04-14 | 2023-03-28 | Sensorion | (+)-azasetron for use in the treatment of ear disorders |
JP6768404B2 (ja) * | 2016-08-12 | 2020-10-14 | 武田テバファーマ株式会社 | パロノセトロン又はその薬学的に許容される塩を含む医薬組成物 |
JP6705348B2 (ja) * | 2016-09-23 | 2020-06-03 | ニプロ株式会社 | 液体製剤、及び、パロノセトロンの安定性を向上する方法 |
GB201618425D0 (en) * | 2016-11-01 | 2016-12-14 | Acacia Pharma Ltd | method |
KR101802183B1 (ko) * | 2016-11-16 | 2017-11-28 | 주식회사 유영제약 | 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물 |
WO2019138162A1 (en) * | 2018-01-12 | 2019-07-18 | Orion Corporation | Palonosetron for the treatment or prevention of nausea and vomiting |
CN108703960A (zh) * | 2018-07-25 | 2018-10-26 | 无锡鑫连鑫生物医药科技有限公司 | 一种帕洛诺司琼缓释微球及其制备方法和使用方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695578A (en) | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
US4937247A (en) | 1985-04-27 | 1990-06-26 | Beecham Group P.L.C. | 1-acyl indazoles |
DE3650772T2 (de) | 1985-04-27 | 2003-04-03 | Hoffmann La Roche | Derivate von Indazole-3-carboxamide und -3-carboxylsäure |
US5578628A (en) | 1985-06-25 | 1996-11-26 | Glaxo Group Limited | Medicaments for the treatment of nausea and vomiting |
GB8516083D0 (en) | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
US5240954A (en) | 1985-06-25 | 1993-08-31 | Glaxo Group Limited | Medicaments |
US4906755A (en) | 1986-11-03 | 1990-03-06 | Merrell Dow Pharmaceuticals Inc. | Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds |
US4707484A (en) | 1986-11-25 | 1987-11-17 | Hoffmann-La Roche Inc. | Substituted piperidinomethylindolone and cyclopent(b)indolone derivatives |
US5011846A (en) | 1988-02-23 | 1991-04-30 | Merrell Dow Pharmaceuticals Inc. | Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof |
GB8914804D0 (en) * | 1989-06-28 | 1989-08-16 | Glaxo Group Ltd | Process |
US5344658A (en) * | 1989-06-28 | 1994-09-06 | Glaxo Group Limited | Process and composition using ondansetron |
AU642178B2 (en) * | 1989-11-28 | 1993-10-14 | Roche Palo Alto Llc | New tricyclic compounds |
US5189041A (en) | 1990-11-16 | 1993-02-23 | Syntex (U.S.A.) Inc. | Tricyclic 5-ht3 receptor antagonists |
US5137893A (en) | 1991-03-07 | 1992-08-11 | G. D. Searle & Co. | Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
US5491148A (en) | 1991-04-26 | 1996-02-13 | Syntex (U.S.A.) Inc. | Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists |
US5272137A (en) * | 1992-02-14 | 1993-12-21 | Mcneil-Pfc, Inc. | Aqueous pharmaceutical suspension for pharmaceutical actives |
GB9305593D0 (en) | 1993-03-18 | 1993-05-05 | Smithkline Beecham Plc | Pharmaceuticals |
US5492914A (en) | 1994-07-28 | 1996-02-20 | Syntex (U.S.A.) Inc. | 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof |
GB9423511D0 (en) | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
GB9423588D0 (en) * | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
GB9625589D0 (en) * | 1996-12-10 | 1997-01-29 | Boots Co Plc | Therapeutic agents |
US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US6294548B1 (en) | 1998-05-04 | 2001-09-25 | Hoffmann-La Roche Inc. | Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride |
AU4551499A (en) * | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-HT3 receptors |
CA2340225A1 (en) * | 1998-10-27 | 2000-05-04 | Wesley Wehsin Han | Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap |
US6196963B1 (en) * | 1999-03-02 | 2001-03-06 | Medtronic Ave, Inc. | Brachytherapy device assembly and method of use |
WO2003100091A1 (en) * | 2002-05-24 | 2003-12-04 | Epidauros Biotechnologie Ag | Means and methods for improved treatment using 'setrones' |
JP5690461B2 (ja) * | 2002-11-15 | 2015-03-25 | ヘルシン ヘルスケア ソシエテ アノニム | 化学療法誘導嘔吐を治療するためのパロノセトロン |
JO2735B1 (en) * | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
US8598219B2 (en) * | 2003-01-30 | 2013-12-03 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
-
2004
- 2004-02-17 MY MYPI20040515A patent/MY143789A/en unknown
- 2004-02-17 TW TW093103716A patent/TWI355936B/zh active
- 2004-02-18 DK DK04712041.5T patent/DK1596862T3/da active
- 2004-02-18 CN CNA2004800045134A patent/CN1750822A/zh active Pending
- 2004-02-18 UA UAA200508834A patent/UA96254C2/uk unknown
- 2004-02-18 PL PL378122A patent/PL378122A1/pl not_active Application Discontinuation
- 2004-02-18 NZ NZ541862A patent/NZ541862A/en unknown
- 2004-02-18 ES ES04712041T patent/ES2357769T3/es not_active Expired - Lifetime
- 2004-02-18 DE DE602004030424T patent/DE602004030424D1/de not_active Expired - Lifetime
- 2004-02-18 AT AT04712041T patent/ATE490774T1/de active
- 2004-02-18 EP EP10177400A patent/EP2258367A3/en not_active Withdrawn
- 2004-02-18 BR BRPI0407549-8A patent/BRPI0407549A/pt not_active Application Discontinuation
- 2004-02-18 KR KR1020057014589A patent/KR101113087B1/ko active IP Right Review Request
- 2004-02-18 CA CA002515946A patent/CA2515946C/en not_active Expired - Fee Related
- 2004-02-18 MX MXPA05008757A patent/MXPA05008757A/es active IP Right Grant
- 2004-02-18 EP EP04712041A patent/EP1596862B1/en not_active Revoked
- 2004-02-18 UY UY28193A patent/UY28193A1/es not_active Application Discontinuation
- 2004-02-18 JP JP2006501881A patent/JP2006517944A/ja active Pending
- 2004-02-18 AU AU2004212704A patent/AU2004212704B2/en not_active Expired
- 2004-02-18 SI SI200431601T patent/SI1596862T1/sl unknown
- 2004-02-18 EA EA200501318A patent/EA013836B1/ru not_active IP Right Cessation
- 2004-02-18 WO PCT/EP2004/001558 patent/WO2004073714A1/en active Application Filing
- 2004-02-18 GE GEAP20048984A patent/GEP20104908B/en unknown
- 2004-02-18 PT PT04712041T patent/PT1596862E/pt unknown
-
2005
- 2005-08-10 US US11/201,035 patent/US20060074101A1/en not_active Abandoned
- 2005-08-11 HR HR20050709A patent/HRP20050709A2/xx not_active Application Discontinuation
- 2005-08-15 IS IS7983A patent/IS7983A/is unknown
- 2005-08-17 CU CU20050158A patent/CU23587B7/es active IP Right Grant
- 2005-08-17 ZA ZA200506580A patent/ZA200506580B/en unknown
- 2005-08-18 EC EC2005005970A patent/ECSP055970A/es unknown
- 2005-09-16 NO NO20054296A patent/NO20054296L/no unknown
- 2005-12-07 HK HK05111169.7A patent/HK1076402A1/xx not_active IP Right Cessation
-
2011
- 2011-03-04 CY CY20111100257T patent/CY1111312T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055970A (es) | Uso de palonosetron para el tratamiento de nausea y vomito post operatorio | |
ES2432164T3 (es) | Composición estabilizada que comprende al menos un compuesto adrenérgico | |
PT1173178E (pt) | Composicao compreendendo apomorfina e sildenafil e utilizacao da mesma para o tratamento da disfuncao erectil | |
CO5611101A2 (es) | Artefactos medicos resistentes a la infeccion | |
KR900015730A (ko) | 정신장해 치료방해 | |
RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
BRPI0519471A2 (pt) | formulaÇço complexa de liberaÇço controlada para administraÇço oral de medicamentos para diabÉticos e mÉtodo para o seu preparo | |
BRPI0816317A2 (pt) | Método para tratar o estresse oxidativo e melhorar a memória de trabalho pela administração de pterostilbeno | |
ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
CA2434484A1 (en) | Compositions comprising ibuprofen and diphenhydramine to treat pain-associated sleep disturbances | |
ES2351665T3 (es) | Derivados de benzamidina para el tratamiento y la prevención de mucositis. | |
SE9901573D0 (sv) | New compounds | |
AU1046302A (en) | Transdermal therapeutic system | |
ES2236551T3 (es) | Combinacion de principios activos para el tratamiento medico de toxicomanias. | |
ES2891548T3 (es) | Composiciones que contienen silicato y métodos de tratamiento | |
SK7532002A3 (en) | Pharmaceutical formulations containing zolmitriptan | |
DE69333387D1 (de) | Pharmazeutische Zusammensetzungen enthaltend Norastemizol. | |
AR043259A1 (es) | Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello | |
ES2244361T1 (es) | Uso del acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular asociada a la edad. | |
ATE536178T1 (de) | Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis | |
CO5251425A1 (es) | Metodo y composiciones para administrar taxanos oralmente a pacientes humanos | |
Bird et al. | Diphenhydramine as a protective agent in a rat model of acute, lethal organophosphate poisoning | |
JP5553306B2 (ja) | 放射線障害防護剤 | |
SE9901572D0 (sv) | New compounds | |
ATE333897T1 (de) | Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen |